{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:23:34Z","timestamp":1786983814835,"version":"build-2736575974"},"reference-count":258,"publisher":"Elsevier","isbn-type":[{"value":"9780443297069","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.acc.2024.06.010","type":"book-chapter","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T02:57:59Z","timestamp":1720407479000},"page":"65-128","source":"Crossref","is-referenced-by-count":3,"title":["Neurofilaments in neurologic disease"],"prefix":"10.1016","author":[{"given":"Christina","family":"Mousele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Holden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilee","family":"Gnanapavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.acc.2024.06.010_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ceb.2020.10.011","article-title":"The dazzling rise of neurofilaments: physiological functions and roles as biomarkers","volume":"68","author":"Bomont","year":"2021","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/bs.acc.2024.06.010_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13024-020-00406-3","article-title":"Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers","volume":"15","author":"Zucchi","year":"2020","journal-title":"Mol. Neurodegen."},{"issue":"4","key":"10.1016\/bs.acc.2024.06.010_bib3","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018309","article-title":"Neurofilaments and neurofilament proteins in health and disease","volume":"9","author":"Yuan","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"11","key":"10.1016\/bs.acc.2024.06.010_bib4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018242","article-title":"Intermediate filaments: structure and assembly","volume":"8","author":"Herrmann","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/bs.acc.2024.06.010_bib5","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1172\/JCI38339","article-title":"Introducing intermediate filaments: from discovery to disease","volume":"119","author":"Eriksson","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2024.06.010_bib6","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1523\/JNEUROSCI.0647-12.2012","article-title":"Expansion of neurofilament medium C terminus increases axonal diameter independent of increases in conduction velocity or myelin thickness","volume":"32","author":"Barry","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.acc.2024.06.010_bib7","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1042\/BST20120101","article-title":"Structures and interactions in \u2018bottlebrush\u2019 neurofilaments: the role of charged disordered proteins in forming hydrogel networks","volume":"40","author":"Beck","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/bs.acc.2024.06.010_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13024-019-0318-4","article-title":"The role of neurofilament aggregation in neurodegeneration: lessons from rare inherited neurological disorders","volume":"14","author":"Didonna","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"4","key":"10.1016\/bs.acc.2024.06.010_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s007950000019","article-title":"Neurofilaments in health and disease","volume":"33","author":"Gotow","year":"2000","journal-title":"Med. Electron. Microsc."},{"key":"10.1016\/bs.acc.2024.06.010_bib10","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1172\/JCI38214","article-title":"Intermediate filaments: primary determinants of cell architecture and plasticity","volume":"119","author":"Herrmann","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jmb.2005.09.092","article-title":"Exploring the mechanical behavior of single intermediate filaments","volume":"354","author":"Kreplak","year":"2005","journal-title":"J. Mol. Biol."},{"issue":"8","key":"10.1016\/bs.acc.2024.06.010_bib12","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/cells10081960","article-title":"Bend, push, stretch: remarkable structure and mechanics of single intermediate filaments and meshworks","volume":"10","author":"Sapra","year":"2021","journal-title":"Cells"},{"key":"10.1016\/bs.acc.2024.06.010_bib13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1083\/jcb.200308159","article-title":"NF-M is an essential target for the myelin-directed \u201coutside- in\u201d signaling cascade that mediates radial axonal growth","volume":"163","author":"Garcia","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/bs.acc.2024.06.010_bib14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1083\/jcb.200308076","article-title":"The neurofilament middle molecular mass subunit carboxyl-terminal tail domains is essential for the radial growth and cytoskeletal architecture of axons but not for regulating neurofilament transport rate","volume":"163","author":"Rao","year":"2003","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1083\/jcb.143.1.171","article-title":"Neurofilament-dependent radial growth of motor axons and axonal organization of neurofilaments does not require the neurofilament heavy subunit (NF-H) or its phosphorylation","volume":"143","author":"Rao","year":"1998","journal-title":"J. Cell Biol."},{"key":"10.1016\/bs.acc.2024.06.010_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00401-016-1564-y","article-title":"Neurofilament depletion improves microtubule dynamics via modulation of Stat3\/stathmin signaling","volume":"132","author":"Yadav","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"35","key":"10.1016\/bs.acc.2024.06.010_bib17","doi-asserted-by":"crossref","first-page":"11043","DOI":"10.1523\/JNEUROSCI.1924-09.2009","article-title":"Neurofilaments bind tubulin and modulate its polymerization","volume":"29","author":"Bocquet","year":"2009","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0896-6273(94)90280-1","article-title":"Neurofilament-deficient axons and perikaryal aggregates in viable transgenic mice expressing a neurofilament-\u03b2-galactosidase fusion protein","volume":"12","author":"Eyer","year":"1994","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cne.903430112","article-title":"The return of phosphorylated and nonphosphorylated epitopes of neurofilament proteins to the regenerating optic nerve of Xenopus laevis","volume":"343","author":"Zhao","year":"1994","journal-title":"J. Comp. Neurol."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/exnr.1997.6654","article-title":"Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments","volume":"148","author":"Zhu","year":"1997","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib21","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1046\/j.1471-4159.1999.0730972.x","article-title":"Disruption of type IV intermediate filament network in mice lacking the neurofilament medium and heavy subunits","volume":"73","author":"Jacomy","year":"1999","journal-title":"J. Neurochem."},{"issue":"27","key":"10.1016\/bs.acc.2024.06.010_bib22","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1523\/JNEUROSCI.23-27-09046.2003","article-title":"Mechanisms of mitochondria-neurofilament interactions","volume":"23","author":"Wagner","year":"2003","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/bs.acc.2024.06.010_bib23","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1096\/fj.09-129585","article-title":"Real-time imaging reveals defects of fast axonal transport induced by disorganization of intermediate filaments","volume":"23","author":"Perrot","year":"2009","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib24","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1096\/fj.11-196345","article-title":"Normal role of the low-molecular-weight neurofilament protein in mitochondrial dynamics and disruption in Charcot-Marie-Tooth disease","volume":"26","author":"Gentil","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/bs.acc.2024.06.010_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.820105","article-title":"Neurofilament light regulates axon caliber, synaptic activity, and organelle trafficking in cultured human motor neurons","volume":"9","author":"Sainio","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/bs.acc.2024.06.010_bib26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.expneurol.2014.10.005","article-title":"Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties","volume":"263","author":"Saporta","year":"2015","journal-title":"Exp. Neurol."},{"issue":"22","key":"10.1016\/bs.acc.2024.06.010_bib27","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1523\/JNEUROSCI.1959-22.2023","article-title":"A new mouse model of giant axonal neuropathy with overt phenotypes and neurodegeneration driven by neurofilament disorganization","volume":"43","author":"Nath","year":"2023","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/bs.acc.2024.06.010_bib28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1083\/jcb.200202037","article-title":"Gene replacement in mice reveals that the heavily phosphorylated tail of neurofilament heavy subunit does not affect axonal caliber or the transit of cargoes in slow axonal transport","volume":"158","author":"Rao","year":"2002","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12035-008-8033-0","article-title":"Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration","volume":"38","author":"Perrot","year":"2008","journal-title":"Mol. Neurobiol."},{"issue":"9","key":"10.1016\/bs.acc.2024.06.010_bib30","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/00001756-200207020-00023","article-title":"Differentiation of adult bone marrow stem cells into neuroprogenitor cells in vitro","volume":"13","author":"Kim","year":"2002","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1523\/JNEUROSCI.18-02-00720.1998","article-title":"Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments","volume":"18","author":"Ehlers","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.acc.2024.06.010_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41398-018-0194-7","article-title":"Neurofilament light interaction with GluN1 modulates neurotransmission and schizophrenia-associated behaviors","volume":"8","author":"Yuan","year":"2018","journal-title":"Transl. Psych."},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.brainresbull.2016.09.002","article-title":"Specialized roles of neurofilament proteins in synapses: relevance to neuropsychiatric disorders","volume":"126","author":"Yuan","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/bs.acc.2024.06.010_bib34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/cm.21597","article-title":"Intermediate filaments in developing neurons: beyond structure","volume":"77","author":"Bott","year":"2020","journal-title":"Cytoskelet"},{"key":"10.1016\/bs.acc.2024.06.010_bib35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mcn.2017.05.010","article-title":"The third wave: intermediate filaments in the maturing nervous system","volume":"84","author":"Kirkcaldie","year":"2017","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/bs.acc.2024.06.010_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2019.101664","article-title":"microRNA dysregulation in neurodegenerative diseases: a systematic review","volume":"182","author":"Ju\u017awik","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/bs.acc.2024.06.010_bib37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.mcn.2007.03.007","article-title":"TDP43 is a human low molecular weight neurofilament (hNFL) mRNA- binding protein","volume":"35","author":"Strong","year":"2007","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/bs.acc.2024.06.010_bib38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1242\/jcs.105817","article-title":"14-3-3 Proteins interact with neurofilament protein-L and regulate dynamic assembly of neurofilaments","volume":"126","author":"Miao","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/bs.acc.2024.06.010_bib39","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1523\/JNEUROSCI.0885-05.2005","article-title":"Aldolases A and C are ribonucleolytic components of a neuronal complex that regulates the stability of the light-neurofilament mRNA","volume":"25","author":"Ca\u00f1ete-Soler","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.acc.2024.06.010_bib40","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nn.3230","article-title":"Divergent roles of ALS-linked proteins FUS\/TLS and TDP-43 intersect in processing long pre-mRNAs","volume":"15","author":"Lagier-Tourenne","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/bs.acc.2024.06.010_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085653","article-title":"Analysis of novel NEFL mRNA targeting microRNAs in amyotrophic lateral sclerosis","volume":"9","author":"Ishtiaq","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2024.06.010_bib42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1756-6606-6-26","article-title":"Altered microRNA expression profile in amyotrophic lateral sclerosis: a role in the regulation of NFL mRNA levels","volume":"6","author":"Campos-Melo","year":"2013","journal-title":"Mol. Brain."},{"key":"10.1016\/bs.acc.2024.06.010_bib43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13041-018-0386-3","article-title":"Dysregulation of human NEFM and NEFH mRNA stability by ALS-linked miRNAs","volume":"11","author":"Campos-Melo","year":"2018","journal-title":"Mol. Brain."},{"key":"10.1016\/bs.acc.2024.06.010_bib44","doi-asserted-by":"crossref","first-page":"49680","DOI":"10.1074\/jbc.M408915200","article-title":"Phylogenetically conserved binding of specific K homology domain proteins to the 3\u2032-untranslated region of the vertebrate middle neurofilament mRNA","volume":"279","author":"Thyagarajan","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2024.06.010_bib45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1101\/gad.13.4.449","article-title":"ELAV tumor antigen, Hel-N1, increases translation of neurofilament M mRNA and induces formation of neurites in human teratocarcinoma cells","volume":"13","author":"Antic","year":"1999","journal-title":"Genes. Dev."},{"key":"10.1016\/bs.acc.2024.06.010_bib46","doi-asserted-by":"crossref","first-page":"1275155","DOI":"10.3389\/fcell.2023.1275155","article-title":"Neurofilaments in health and Charcot-Marie-Tooth disease","volume":"11","author":"Kotaich","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/bs.acc.2024.06.010_bib47","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/cm.21679","article-title":"Posttranslational modifications of the cytoskeleton","volume":"78","author":"MacTaggart","year":"2021","journal-title":"Cytoskelet"},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1083\/jcb.78.2.R23","article-title":"Neurofilament protein is phosphorylated in the squid giant axon","volume":"78","author":"Pant","year":"1978","journal-title":"J. Cell Biol."},{"key":"10.1016\/bs.acc.2024.06.010_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/382107","article-title":"Neurofilament phosphorylation during development and disease: which came first, the phosphorylation or the accumulation?","author":"Dale","year":"2012","journal-title":"J. Amino Acids."},{"key":"10.1016\/bs.acc.2024.06.010_bib50","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1529-8027.2012.00434.x","article-title":"Neurofilament phosphorylation and their proline-directed kinases in health and disease","volume":"17","author":"Holmgren","year":"2012","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/bs.acc.2024.06.010_bib51","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.yexcr.2007.04.010","article-title":"Role of phosphorylation on the structural dynamics and function of types III and IV intermediate filaments","volume":"313","author":"Sihag","year":"2007","journal-title":"Exp. Cell Res."},{"key":"10.1016\/bs.acc.2024.06.010_bib52","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1523\/JNEUROSCI.5299-06.2007","article-title":"Conditional NF-L transgene expression in mice for in vivo analysis of turnover and transport rate of neurofilaments","volume":"27","author":"Millecamps","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.acc.2024.06.010_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/bs.mie.2015.07.009","article-title":"Degradation of the intermediate filament family by gigaxonin","volume":"569","author":"Bomont","year":"2016","journal-title":"Meth. Enzymol."},{"key":"10.1016\/bs.acc.2024.06.010_bib54","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3389\/fphys.2020.01022","article-title":"E3 ubiquitin ligases in neurological diseases: focus on gigaxonin and autophagy","volume":"11","author":"Lescouz\u00e8res","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/bs.acc.2024.06.010_bib55","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/hmg\/ddw081","article-title":"Intermediate filament aggregates cause mitochondrial dysmotility and increase energy demands in giant axonal neuropathy","volume":"25","author":"Israeli","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/bs.acc.2024.06.010_bib56","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41467-019-08331-w","article-title":"Gigaxonin E3 ligase governs ATG16L1 turnover to control autophagosome production","volume":"10","author":"Scrivo","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.acc.2024.06.010_bib57","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1080\/15548627.2019.1628546","article-title":"GAN (gigaxonin) E3 ligase and ATG16L1: master and commander of autophagosome production","volume":"15","author":"Bomont","year":"2019","journal-title":"Autophagy"},{"key":"10.1016\/bs.acc.2024.06.010_bib58","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2024.06.010_bib59","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jim.2009.09.014","article-title":"Neurofilament ELISA validation","volume":"352","author":"Petzold","year":"2010","journal-title":"J. Immunol. Meth."},{"key":"10.1016\/bs.acc.2024.06.010_bib61","article-title":"Breakthrough device designation granted to Roche\u2019s elecsys neurofilament light chain test for multiple sclerosis","year":"2023","journal-title":"Pract. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib62","doi-asserted-by":"crossref","first-page":"75091","DOI":"10.1371\/journal.pone.0075091","article-title":"Increased neurofilament light chain blood levels in neurodegenerative neurological diseases","volume":"8","author":"Gaiottino","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2024.06.010_bib63","article-title":"Blood biomarker test granted breakthrough device status by FDA","author":"Shapiro","year":"2022","journal-title":"Multiple Scler. N. Today"},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib64","doi-asserted-by":"crossref","first-page":"045","DOI":"10.1093\/braincomms\/fcac045","article-title":"A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer\u2019s disease","volume":"4","author":"Budelier","year":"2022","journal-title":"Brain Commun."},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib65","doi-asserted-by":"crossref","first-page":"067","DOI":"10.1093\/braincomms\/fcad067","article-title":"Uman-type neurofilament light antibodies are effective reagents for the imaging of neurodegeneration","volume":"5","author":"Shaw","year":"2023","journal-title":"Brain Commun."},{"key":"10.1016\/bs.acc.2024.06.010_bib66","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1212\/NXI.0000000000000271","article-title":"Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS","volume":"3","author":"Bergman","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/bs.acc.2024.06.010_bib67","series-title":"Brain Neurotrauma: Molecular, Neuro-Psychological, and Rehabilitation Aspects","first-page":"21","article-title":"The use and potential of pNF-H as a general blood biomarker of axonal loss: an immediate application for CNS injury","author":"Shaw","year":"2015"},{"issue":"11","key":"10.1016\/bs.acc.2024.06.010_bib68","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1093\/brain\/awad234","article-title":"Peripherin is a biomarker of axonal damage in peripheral nervous system disease","volume":"146","author":"Keddie","year":"2023","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib69","first-page":"18","article-title":"The prognostic utility of neurofilament light chain in multiple sclerosis: a narrative review","volume":"23","author":"Itorralba","year":"2024","journal-title":"Pract. Neurol. (US)"},{"issue":"8","key":"10.1016\/bs.acc.2024.06.010_bib70","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024117","article-title":"Clinical spectrum of amyotrophic lateral sclerosis (ALS)","volume":"7","author":"Grad","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/bs.acc.2024.06.010_bib71","first-page":"61","article-title":"Pathology of amyotrophic lateral sclerosis","volume":"36","author":"Hughes","year":"1982","journal-title":"Adv. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib72","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0014-4886(79)90129-8","article-title":"Degeneration of the human Betz cell due to amyotrophic lateral sclerosis","volume":"63","author":"Hammer","year":"1979","journal-title":"Exp. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib73","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000351153","article-title":"Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature","volume":"41","author":"Chio","year":"2013","journal-title":"Neuroepidemiol"},{"key":"10.1016\/bs.acc.2024.06.010_bib74","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jnnp.2009.183525","article-title":"Incidence of amyotrophic lateral sclerosis in Europe","volume":"81","author":"Logroscino","year":"2010","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"10.1016\/bs.acc.2024.06.010_bib75","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/brain\/aws144","article-title":"Young-onset amyotrophic lateral sclerosis: historical and other observations","volume":"135","author":"Turner","year":"2012","journal-title":"Brain"},{"key":"10.1016\/bs.acc.2024.06.010_bib76","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.0b013e3181b6bbbd","article-title":"ALS motor phenotype het- erogeneity, focality, and spread: deconstructing motor neuron degeneration","volume":"73","author":"Ravits","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib77","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature09320","article-title":"Ataxin-2 intermediate-length polyglutamine ex-pansions are associated with increased risk for ALS","volume":"466","author":"Elden","year":"2010","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2024.06.010_bib78","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1212\/01.wnl.0000261045.57095.56","article-title":"Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem","volume":"68","author":"Ravits","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib79","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mus.20728","article-title":"Primary lateral sclerosis","volume":"35","author":"Singer","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/bs.acc.2024.06.010_bib80","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1212\/WNL.0b013e3181c1dea3","article-title":"Study of 962 patients indicates progressive muscular atrophy is a form of ALS","volume":"73","author":"Kim","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib81","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1212\/01.WNL.0000163995.62871.A4","article-title":"Hemiplegic ALS: Mills syndrome","volume":"64","author":"Rajabally","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib82","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1212\/01.WNL.0000055861.95202.8D","article-title":"Are amyotrophic lateral sclerosis patients cognitively normal?","volume":"60","author":"Lomen-Hoerth","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib83","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00005072-198409000-00002","article-title":"Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis","volume":"43","author":"Hirano","year":"1984","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib84","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/jnen\/59.11.972","article-title":"Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis","volume":"59","author":"Wong","year":"2000","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib85","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/00005072-199910000-00009","article-title":"Extra neurofilament NF-L subunits rescue motor neuron disease caused by overexpression of the human NF-H gene in mice","volume":"58","author":"Meier","year":"1999","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"16","key":"10.1016\/bs.acc.2024.06.010_bib86","doi-asserted-by":"crossref","first-page":"9631","DOI":"10.1073\/pnas.95.16.9631","article-title":"Absence of neurofilaments reduces the selective vulnerability of motor neurons and slowsdisease caused by a familial amyotrophic lateral sclerosis- linked superoxidedismutase 1 mutant","volume":"95","author":"Williamson","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.acc.2024.06.010_bib87","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1046\/j.1471-4159.1996.67052013.x","article-title":"Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF","volume":"67","author":"Rosengren","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/bs.acc.2024.06.010_bib88","first-page":"0164625","article-title":"Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"11","author":"Xu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2024.06.010_bib89","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1468-1331.2007.01972.x","article-title":"Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype","volume":"14","author":"Zetterberg","year":"2007","journal-title":"Eur. J. Neurol."},{"issue":"17","key":"10.1016\/bs.acc.2024.06.010_bib90","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.3390\/ijms20174152","article-title":"Diagnostic and prognostic role of blood and cerebrospinal fluid and blood neurofilaments in amyotrophic lateral sclerosis: a review of the literature","volume":"20","author":"Gagliardi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.acc.2024.06.010_bib91","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Lu","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib92","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/j.1468-1331.2012.03777.x","article-title":"Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression","volume":"19","author":"Tortelli","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib93","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ene.12421","article-title":"Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis","volume":"22","author":"Tortelli","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib94","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/acn3.212","article-title":"CSF neurofilament light chain reflects corticospinal tract degeneration in ALS","volume":"2","author":"Menke","year":"2015","journal-title":"Ann. Clin. Trans. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib95","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/21678421.2016.1167913","article-title":"Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS","volume":"17","author":"Oeckl","year":"2016","journal-title":"Amyotr. Later. Scler. Frontotemp. Degen."},{"key":"10.1016\/bs.acc.2024.06.010_bib96","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp-2012-303768","article-title":"Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Boylan","year":"2013","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"10.1016\/bs.acc.2024.06.010_bib97","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ana.24980","article-title":"Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis","volume":"82","author":"Gendron","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib98","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3109\/21678421.2014.884592","article-title":"Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis","volume":"15","author":"Lehnert","year":"2014","journal-title":"Amyotr. Later. Scler. Frontotemp. Degen."},{"key":"10.1016\/bs.acc.2024.06.010_bib99","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jns.2015.04.032","article-title":"Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis","volume":"353","author":"McCombe","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/bs.acc.2024.06.010_bib100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jns.2016.05.062","article-title":"Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis","volume":"367","author":"Li","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/bs.acc.2024.06.010_bib101","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/jnnp-2017-316605","article-title":"Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis","volume":"89","author":"De Schaepdryver","year":"2017","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"10.1016\/bs.acc.2024.06.010_bib102","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1471-4159.2011.07224.x","article-title":"Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS","volume":"117","author":"Ganesalingam","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/bs.acc.2024.06.010_bib103","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1515\/cclm-2018-0147","article-title":"Commutability of the certified reference materials for the standardization of beta-amyloid 1\u201342 assay in human cerebrospinal fluid: lessons for tau and beta-amyloid 1\u201340 measurements.","volume":"56","author":"Andreasson","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2024.06.010_bib104","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/2472630317750378","article-title":"Automation on an open-access platform of Alzheimer\u2019s disease biomarker immunoassays","volume":"23","author":"Gille","year":"2018","journal-title":"SLAS Technol."},{"key":"10.1016\/bs.acc.2024.06.010_bib105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ana.25276","article-title":"Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion","volume":"84","author":"Benatar","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib106","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1212\/WNL.0000000000004029","article-title":"Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease","volume":"88","author":"Poesen","year":"2017","journal-title":"Neurology"},{"issue":"7-8","key":"10.1016\/bs.acc.2024.06.010_bib107","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/21678421.2019.1646769","article-title":"Neurofilaments in pre-symptomatic ALS and the impact of genotype","volume":"20","author":"Benatar","year":"2019","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"10.1016\/bs.acc.2024.06.010_bib108","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jalz.2010.01.009","article-title":"Alzheimer\u2019s Association. 2010 Alzheimer\u2019s disease facts and figures","volume":"6","year":"2010","journal-title":"Alzheim. Dement."},{"key":"10.1016\/bs.acc.2024.06.010_bib109","first-page":"168","article-title":"The proteome of neurofilament-containing protein aggregates in blood","volume":"14","author":"Adiutori","year":"2018","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/bs.acc.2024.06.010_bib110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/jnc.14542","article-title":"A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry","volume":"146","author":"Zucchi","year":"2018","journal-title":"J. Neurochem."},{"key":"10.1016\/bs.acc.2024.06.010_bib111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jns.2006.05.069","article-title":"Preventing familial amyotrophic lateral sclerosis: is a clinical trial feasible?","volume":"251","author":"Benatar","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/bs.acc.2024.06.010_bib112","article-title":"Predicting the risk of disease in familial amyotrophic lateral sclerosis","author":"Benatar","year":"2008","journal-title":"Am. Neurological Assoc. 133rd Annu. Meet."},{"key":"10.1016\/bs.acc.2024.06.010_bib113","first-page":"12","article-title":"Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients","volume":"87","author":"Steinacker","year":"2016","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"10.1016\/bs.acc.2024.06.010_bib114","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1212\/WNL.0b013e31828f18ac","article-title":"Cognitive changes predict functional decline in ALS: a population-based longitudinal study","volume":"80","author":"Elamin","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib115","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2024.06.010_bib116","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib117","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/jnnp-2014-307672","article-title":"Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study","volume":"86","author":"Lu","year":"2015","journal-title":"J. Neurol. Neurosurg. Psych."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib118","doi-asserted-by":"crossref","first-page":"22128","DOI":"10.1038\/s41598-021-01499-6","article-title":"Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics","volume":"11","author":"Behzadi","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.acc.2024.06.010_bib119","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","article-title":"Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers","volume":"88","author":"Reitz","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/bs.acc.2024.06.010_bib120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.gene.2016.10.022","article-title":"Integrated late onset Alzheimer\u2019s disease (LOAD) susceptibility genes: cholesterol metabolism and trafficking perspectives","volume":"597","author":"Dong","year":"2017","journal-title":"Gene"},{"issue":"6","key":"10.1016\/bs.acc.2024.06.010_bib121","first-page":"2020","article-title":"Biochemical markers in Alzheimer\u2019s disease","volume":"21","author":"Rabbito","year":"1989","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/bs.acc.2024.06.010_bib122","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib123","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Dominantly Inherited Alzheimer Network. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/bs.acc.2024.06.010_bib124","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00401-011-0845-8","article-title":"A harmonized classification system for FTLD-TDP pathology","volume":"122","author":"Mackenzie","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/bs.acc.2024.06.010_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","article-title":"Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update","volume":"119","author":"MacKenzie","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"4","key":"10.1016\/bs.acc.2024.06.010_bib127","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40520-020-01554-8","article-title":"The role of neurofilament light chain in frontotemporal dementia: a meta-analysis","volume":"33","author":"Karantali","year":"2021","journal-title":"Aging Clin. Exp. Res."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13195-017-0331-1","article-title":"The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias","volume":"10","author":"Abu-Rumeileh","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.24052","article-title":"Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration","volume":"75","author":"Scherling","year":"2014","journal-title":"Ann. Neurol."},{"issue":"13","key":"10.1016\/bs.acc.2024.06.010_bib130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","article-title":"Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia","volume":"87","author":"Rohrer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib131","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/brain\/awr361","article-title":"Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical, and neuropathological features","volume":"135","author":"Mahoney","year":"2012","journal-title":"Brain"},{"key":"10.1016\/bs.acc.2024.06.010_bib132","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1474-4422(14)70324-2","article-title":"Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis","volume":"14","author":"Rohrer","year":"2015","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib133","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/bs.acc.2024.06.010_bib134","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00702-023-02632-7","article-title":"Blood neurofilament light chain in Parkinson\u2019s disease","volume":"130","author":"Buhmann","year":"2023","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"10","key":"10.1016\/bs.acc.2024.06.010_bib135","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib136","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","article-title":"Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases","volume":"91","author":"Bacioglu","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/bs.acc.2024.06.010_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.690013","article-title":"Neurofilament levels are reflecting the loss of presynaptic dopamine receptors in movement disorders","volume":"15","author":"Diekamper","year":"2021","journal-title":"Front. Neurosci."},{"issue":"11","key":"10.1016\/bs.acc.2024.06.010_bib138","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/mds.28206","article-title":"Validation of serum neurofilament light chain as a biomarker of Parkinson\u2019s disease progression","volume":"35","author":"Mollenhauer","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.acc.2024.06.010_bib139","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.parkreldis.2021.07.028","article-title":"Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson\u2019s disease (MARK-PD)","volume":"90","author":"Niemann","year":"2021","journal-title":"Parkin. Relat. Disord."},{"issue":"11","key":"10.1016\/bs.acc.2024.06.010_bib140","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1212\/WNL.0000000000008088","article-title":"Blood NfL: a biomarker for disease severity and progression in Parkinson disease","volume":"93","author":"Lin","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib141","doi-asserted-by":"crossref","first-page":"17368","DOI":"10.1038\/s41598-018-35766-w","article-title":"Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease","volume":"8","author":"Lin","year":"2018","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/bs.acc.2024.06.010_bib142","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/WNL.0000000000007179","article-title":"Serum NFL discriminates Parkinson disease from atypical parkinsonisms","volume":"92","author":"Marques","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib143","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.parkreldis.2021.07.028","article-title":"Serum neurofilament is associated with motor function, cognitive decline, and subclinical cardiac damage in advanced Parkinson\u2019s disease (MARK-PD)","volume":"90","author":"Niemann","year":"2021","journal-title":"Parkin. Relat. Disord."},{"issue":"12","key":"10.1016\/bs.acc.2024.06.010_bib144","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: a critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.parkreldis.2021.02.008","article-title":"Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson\u2019s disease: an 8-year longitudinal study","volume":"85","author":"Ye","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib146","first-page":"95","article-title":"Serum neurofilament light chain and postural instability\/gait difficulty (PIGD) subtypes of Parkinson\u2019s disease in the MARK-PD study","volume":"129","author":"Potter-Nerger","year":"2022","journal-title":"J. Neural Transm. (Vienna)."},{"issue":"12","key":"10.1016\/bs.acc.2024.06.010_bib147","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/mds.28779","article-title":"Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease","volume":"6","author":"Aamodt","year":"2021","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib148","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3233\/JPD-212535","article-title":"Serum neurofilament dynamics predicts cognitive progression in de novo Parkinson\u2019s disease","volume":"11","author":"Ma","year":"2021","journal-title":"J. Parkin. Dis."},{"issue":"10","key":"10.1016\/bs.acc.2024.06.010_bib149","first-page":"1277","article-title":"Association of cerebrospinal fluid beta-amyloid 1\u201342, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease","volume":"70","author":"Kang","year":"2013","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/bs.acc.2024.06.010_bib150","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/brain\/awp234","article-title":"A clinico-pathological study of subtypes in Parkinson\u2019s disease","volume":"132","author":"Selikhova","year":"2009","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib151","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/mds.28909","article-title":"Age-adjusted serum neurofilament predicts cognitive decline in Parkinson\u2019s disease (MARK-PD)","volume":"37","author":"Buhmann","year":"2022","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/bs.acc.2024.06.010_bib152","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/mds.28026","article-title":"Intraindividual neurofilament dynamics in serum mark the conversion to sporadic Parkinson\u2019s disease","volume":"35","author":"Wilke","year":"2020","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/bs.acc.2024.06.010_bib153","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.3390\/ijms24076051","article-title":"Peripheral biomarkers in manifest and premanifest Huntington\u2019s disease","volume":"24","author":"Morena","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/bs.acc.2024.06.010_bib154","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JHD-170273","article-title":"A critical evaluation of wet biomarkers for Huntington\u2019s disease: current status and ways forward","volume":"7","author":"Silajd\u017ei\u0107","year":"2018","journal-title":"J. Huntingt. Dis."},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib156","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.parkreldis.2008.05.012","article-title":"Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington\u2019s disease","volume":"15","author":"Constantinescu","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"issue":"9","key":"10.1016\/bs.acc.2024.06.010_bib157","doi-asserted-by":"crossref","first-page":"0163479","DOI":"10.1371\/journal.pone.0163479","article-title":"Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington\u2019s disease","volume":"11","author":"Rodrigues","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/bs.acc.2024.06.010_bib158","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1212\/NXI.0000000000000287","article-title":"Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease","volume":"3","author":"Vinther-Jensen","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"issue":"8","key":"10.1016\/bs.acc.2024.06.010_bib159","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"issue":"458","key":"10.1016\/bs.acc.2024.06.010_bib160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7108","article-title":"Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease","volume":"10","author":"Byrne","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib161","doi-asserted-by":"crossref","first-page":"0172762","DOI":"10.1371\/journal.pone.0172762","article-title":"Tau or neurofilament light \u2013 which is the more suitable biomarker for Huntington\u2019s disease?","volume":"12","author":"Niemela","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/bs.acc.2024.06.010_bib162","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/bs.acc.2024.06.010_bib163","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1212\/WNL.0000000000005005","article-title":"Neurofilament light protein in blood predicts regional atrophy in Huntington disease","volume":"90","author":"Johnson","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib164","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S1474-4422(06)70581-6","article-title":"Sex ratio of multiple sclerosis in Canada: a longitudinal study","volume":"5","author":"Orton","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib165","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1212\/WNL.0b013e3182872855","article-title":"Disability in multiple sclerosis: a reference for patients and clinicians","volume":"80","author":"Kister","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib166","first-page":"114","article-title":"Multidisciplinary rehabilitation for adults with multiple sclerosis","volume":"79","author":"Khan","year":"2008","journal-title":"J. Neurol. Neurosurg. Psych."},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib167","first-page":"95","article-title":"The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis","volume":"2","author":"Holloman","year":"2013","journal-title":"Am. J. Stem Cells."},{"key":"10.1016\/bs.acc.2024.06.010_bib168","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2024.06.010_bib169","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.wco.0000169736.60922.20","article-title":"The spectrum of multiple sclerosis: new lessons from pathology","volume":"18","author":"Bruck","year":"2005","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-2007-1019125","article-title":"Genetics and natural history of multiple sclerosis","volume":"28","author":"Kantarci","year":"2008","journal-title":"Semin. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib171","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"Sawcer","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib172","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ana.21117","article-title":"Environmental risk factors for multiple sclerosis. Part I: The role of infection","volume":"6","author":"Ascherio","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib173","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ana.21141","article-title":"Environmental risk factors for multiple sclerosis. Part II: Non-infectious factors","volume":"61","author":"Ascherio","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib174","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1001\/jama.296.23.2832","article-title":"Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis","volume":"296","author":"Munger","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2024.06.010_bib175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1586\/14737175.2013.865866","article-title":"Environmental factors in multiple sclerosis","volume":"13","author":"Ascherio","year":"2013","journal-title":"Exp. Rev. Neurother."},{"key":"10.1016\/bs.acc.2024.06.010_bib176","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1471-2377-11-123","article-title":"Environmental factors in early childhood are associated with multiple sclerosis: a case-control study","volume":"11","author":"Conradi","year":"2011","journal-title":"BMC Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib177","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1756285611425694","article-title":"Smoking: effects on multiple sclerosis susceptibility and disease progression","volume":"5","author":"Wingerchuk","year":"2012","journal-title":"Therapeut. Advan. Neurol. Dis."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib178","first-page":"1","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J."},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib179","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1212\/NXI.0000000000000708","article-title":"Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"7","author":"Kim","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"issue":"13","key":"10.1016\/bs.acc.2024.06.010_bib180","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib181","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.msard.2019.02.009","article-title":"Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease","volume":"30","author":"Peng","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib182","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis","volume":"77","author":"Bjornevik","year":"2019","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/bs.acc.2024.06.010_bib183","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/brain\/awy021","article-title":"Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome","volume":"141","author":"Matute-Blanch","year":"2018","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib184","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","article-title":"Clinically isolated syndromes","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/bs.acc.2024.06.010_bib185","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1177\/1352458518775303","article-title":"High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome","volume":"25","author":"van der Vuurst de Vries","year":"2019","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/bs.acc.2024.06.010_bib186","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/bs.acc.2024.06.010_bib187","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/WNL.0000000000003085","article-title":"Neurofilament light chain level is a weak risk factor for the development of MS","volume":"87","author":"Arrambide","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102807","article-title":"Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study","volume":"56","author":"Bittner","year":"2020","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/bs.acc.2024.06.010_bib189","first-page":"733","article-title":"Prognostic value of serum neurofilaments in patients with clinically isolated syndromes","volume":"92","author":"Alla Costa","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib190","article-title":"Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury","author":"Friedauer","year":"2024","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/bs.acc.2024.06.010_bib191","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1177\/1352458515623365","article-title":"Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity","volume":"22","author":"Kuhle","year":"2016","journal-title":"Mult. Scler."},{"issue":"22","key":"10.1016\/bs.acc.2024.06.010_bib192","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib193","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/NXI.0000000000000422","article-title":"Neurofilament light chain predicts disease activity in relapsing-remitting MS","volume":"5","author":"Varhaug","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"issue":"4","key":"10.1016\/bs.acc.2024.06.010_bib194","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ana.25197","article-title":"Inflammatory intrathecal profiles and cortical damage in multiple sclerosis","volume":"83","author":"Magliozzi","year":"2018","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib195","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/1352458519901272","article-title":"Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis","volume":"27","author":"Srpova","year":"2021","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/bs.acc.2024.06.010_bib196","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"issue":"5","key":"10.1016\/bs.acc.2024.06.010_bib197","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1352458518765666","article-title":"Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis","volume":"25","author":"Siller","year":"2019","journal-title":"Mult. Scler."},{"issue":"22","key":"10.1016\/bs.acc.2024.06.010_bib198","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/bs.acc.2024.06.010_bib199","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamaneurol.2019.2137","article-title":"Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years","volume":"76","author":"Canto","year":"2019","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/bs.acc.2024.06.010_bib200","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1177\/1352458518782005","article-title":"Neurofilaments and 10-year follow-up in multiple sclerosis","volume":"24","author":"Bhan","year":"2018","journal-title":"Mult. Scler."},{"issue":"23","key":"10.1016\/bs.acc.2024.06.010_bib201","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1212\/WNL.0000000000009571","article-title":"Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis","volume":"94","author":"Manouchehrinia","year":"2020","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/bs.acc.2024.06.010_bib202","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/acn3.638","article-title":"Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis","volume":"5","author":"Chitnis","year":"2018","journal-title":"Ann. Clin. Transl. Neur."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib203","doi-asserted-by":"crossref","first-page":"10381","DOI":"10.1038\/s41598-020-67504-6","article-title":"Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis","volume":"10","author":"Thebault","year":"2020","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/bs.acc.2024.06.010_bib204","first-page":"1324","article-title":"Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients","volume":"90","author":"Sejbaek","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"8","key":"10.1016\/bs.acc.2024.06.010_bib205","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14737175.2020.1760846","article-title":"Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring","volume":"20","author":"Preziosa","year":"2020","journal-title":"Exp. Rev. Neurother."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib206","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1352458519872891","article-title":"Serum NFL levels should be used to monitor multiple sclerosis evolution-No","volume":"26","author":"Myhr","year":"2020","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/bs.acc.2024.06.010_bib207","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1212\/WNL.0000000000009097","article-title":"Blood neurofilament light levels segregate treatment effects in multiple sclerosis","volume":"94","author":"Delcoigne","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/bs.acc.2024.06.010_bib208","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.acc.2024.06.010_bib209","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/acn3.795","article-title":"Blood neurofilament light as a potential endpoint in phase 2 studies in MS","volume":"6","author":"Sormani","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"11","key":"10.1016\/bs.acc.2024.06.010_bib210","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41582-019-0271-4","article-title":"Trials take MS treatment forward","volume":"15","author":"Fyfe","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/bs.acc.2024.06.010_bib211","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib212","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/bs.acc.2024.06.010_bib213","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/ene.13687","article-title":"Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain","volume":"25","author":"Quintana","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib214","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.S12.009","article-title":"The predictive value of neurofilament light chain levels in blood for cognitive impairment in patients with secondary progressive multiple sclerosis","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib215","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41598-020-57895-x","article-title":"Continuous reorganization of cortical information flow in multiple sclerosis: a longitudinal fMRI effective connectivity study","volume":"10","author":"Fleischer","year":"2020","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/bs.acc.2024.06.010_bib216","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/acn3.50872","article-title":"Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study","volume":"6","author":"Jakimovski","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib217","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1352458518819380","article-title":"Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity","volume":"26","author":"Hogel","year":"2020","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/bs.acc.2024.06.010_bib218","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000142988.49341.D1","article-title":"Neurofilament and glial fibrillary acidic protein in multiple sclerosis","volume":"63","author":"Norgren","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib219","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fneur.2020.00608","article-title":"A score based on NfL and glial markers may differentiate between relapsing-remitting and progressive MS course","volume":"11","author":"Huss","year":"2020","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib220","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/NXI.0000000000000679","article-title":"Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS","volume":"7","author":"Engel","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib221","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12974-017-0812-y","article-title":"Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study","volume":"14","author":"Farina","year":"2017","journal-title":"J. Neuroinflamm."},{"issue":"5","key":"10.1016\/bs.acc.2024.06.010_bib222","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1212\/NXI.0000000000000595","article-title":"Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS","volume":"6","author":"Engel","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib223","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/acn3.51298","article-title":"CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis","volume":"8","author":"Magliozzi","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib224","first-page":"207","article-title":"Charcot- Marie-Tooth disease and hereditary motor neuropathies \u2013 update 2020","volume":"32","author":"Rudnik-Sch\u00f6neborn","year":"2020","journal-title":"Med. Genet."},{"key":"10.1016\/bs.acc.2024.06.010_bib225","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41582-019-0254-5","article-title":"Next-generation sequencing in Charcot-Marie-Tooth disease: opportunities and challenges","volume":"15","author":"Pipis","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib226","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00415-017-8474-3","article-title":"Intermediate Charcot\u2013Marie\u2013Tooth disease: an electrophysiological reappraisal and systematic review","volume":"264","author":"Berciano","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib227","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nrneurol.2013.179","article-title":"Clinical implications of genetic advances in Charcot-Marie-Tooth disease","volume":"9","author":"Rossor","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib228","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/cm.21676","article-title":"A review and analysis of the clinical literature on Charcot\u2013Marie\u2013Tooth disease caused by mutations in neurofilament protein L","volume":"78","author":"Stone","year":"2021","journal-title":"Cytoskeleton"},{"key":"10.1016\/bs.acc.2024.06.010_bib229","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/jns.12454","article-title":"Proximal weakness involvement in the first Italian case of Charcot-Marie-Tooth 2CC harboring a novel frameshift variant in NEFH","volume":"26","author":"Aruta","year":"2021","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib230","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/ene.14689","article-title":"Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease","volume":"28","author":"Millere","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/bs.acc.2024.06.010_bib231","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1212\/WNL.0000000000004932","article-title":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies","volume":"90","author":"Sandelius","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.acc.2024.06.010_bib232","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1212\/WNL.0000000000001773","article-title":"Reduced neurofilament expression in cutaneous nerve fibers of patients with CMT2E","volume":"85","author":"Pisciotta","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/bs.acc.2024.06.010_bib233","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1212\/01.WNL.0000120664.07186.3C","article-title":"Giant axon and neurofilament accumulation in Charcot-Marie-Tooth disease type 2E","volume":"62","author":"Fabrizi","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/bs.acc.2024.06.010_bib234","article-title":"GJB1 disorders: Charcot-Marie-Tooth neuropathy (CMT1X) and central nervous system phenotypes","author":"Abrams","year":"1998","journal-title":"GeneReviews\u00ae Internet"},{"issue":"8","key":"10.1016\/bs.acc.2024.06.010_bib235","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/bs.acc.2024.06.010_bib236","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology. A systematic review and meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/bs.acc.2024.06.010_bib237","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41419-020-02798-y","article-title":"Developmental demands contribute to early neuromuscular degeneration in CMT2D mice","volume":"11","author":"Sleigh","year":"2020","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib238","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jns.12477","article-title":"A longitudinal and cross-sectional study of plasma neurofilament light chain concentration in Charcot-Marie-Tooth disease","volume":"27","author":"Rossor","year":"2022","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"9","key":"10.1016\/bs.acc.2024.06.010_bib239","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/ene.15428","article-title":"Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies","volume":"29","author":"Kmezic","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/bs.acc.2024.06.010_bib240","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib241","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12974-020-01737-0","article-title":"Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barr\u00e9 syndrome","volume":"17","author":"Altmann","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/bs.acc.2024.06.010_bib242","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1093\/brain\/aww247","article-title":"syndrome in the 100 years since its description by Guillain, Barr\u00e9 and Strohl","volume":"139","author":"Hughes","year":"2016","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib243","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/bs.acc.2024.06.010_bib244","first-page":"CD001798","article-title":"Plasma exchange for Guillain-Barr\u00e9 syndrome","author":"Rapha\u00ebl","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/bs.acc.2024.06.010_bib245","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome","volume":"6","author":"van Koningsveld","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib246","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0959-4388(99)00004-5","article-title":"Neurofilament functions in health and disease","volume":"9","author":"Julien","year":"1999","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/bs.acc.2024.06.010_bib247","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ane.12927","article-title":"Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barr\u00e9 syndrome: a pilot study","volume":"138","author":"Axelsson","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/bs.acc.2024.06.010_bib248","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105072","article-title":"Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barr\u00e9 syndrome","volume":"102","author":"Van Tilburg","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib249","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp-2020-323899","article-title":"Serum neu- rofilament light chain predicts long-term prognosis in Guillain- Barr\u00e9 syndrome patients","volume":"92","author":"Mart\u00edn-Aguilar","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/bs.acc.2024.06.010_bib250","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinph.2012.01.025","article-title":"Electrodiagnostic criteria for Guillain-Barr\u00e8 syndrome: a critical revision and the need for an update","volume":"123","author":"Uncini","year":"2012","journal-title":"Clin. Neurophysiol."},{"issue":"5","key":"10.1016\/bs.acc.2024.06.010_bib251","doi-asserted-by":"crossref","first-page":"02084","DOI":"10.1002\/brb3.2084","article-title":"Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy","volume":"11","author":"Hayashi","year":"2021","journal-title":"Brain Behav."},{"issue":"6","key":"10.1016\/bs.acc.2024.06.010_bib252","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200162","article-title":"Peptides from the variable domain of immunoglobulin G as biomarkers in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"10","author":"Godelaine","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/bs.acc.2024.06.010_bib253","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/jnnp-2014-309916","article-title":"Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies","volume":"86","author":"Doppler","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/bs.acc.2024.06.010_bib254","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/jns.12279","article-title":"Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies","volume":"23","author":"Mariotto","year":"2018","journal-title":"J. Peripheral Nerv. Syst."},{"issue":"10","key":"10.1016\/bs.acc.2024.06.010_bib255","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1007\/s00415-021-10537-2","article-title":"Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients","volume":"268","author":"Fukami","year":"2021","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/bs.acc.2024.06.010_bib256","doi-asserted-by":"crossref","first-page":"018","DOI":"10.1093\/braincomms\/fcab018","article-title":"Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy","volume":"3","author":"Godelaine","year":"2021","journal-title":"Brain Commun."},{"issue":"11","key":"10.1016\/bs.acc.2024.06.010_bib257","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1111\/ene.15496","article-title":"Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"29","author":"Kapoor","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/bs.acc.2024.06.010_bib258","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrneurol.2011.175","article-title":"Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies","volume":"8","author":"Vlam","year":"2012","journal-title":"Nat. Rev. Neurol."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242324001033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242324001033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:52:48Z","timestamp":1724413968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242324001033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443297069"],"references-count":258,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2024.06.010","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}